论文部分内容阅读
应用 LCN,ERFC,LCT,和 LCM 等指标观察到未经抗癌治疗的初诊癌症病人的免疫状态较正常人有降低倾向,癌灶转移病人与未转移者比较,淋巴细胞反应有所偏低,但多数指标无统计学意义,不同抗癌治疗的病人和初诊病人比较,放射对 ERFC、LCT 和 LCM 有抑制作用,化疗病人的 LCN 和 ERFC 降低,中草药抗癌药仅有 LCT 降低,而手术治疗与综合疗法则未见明显变化,淋巴细胞的各项免疫指标与治疗后病人的病情发展关系,并不完全相符,因此,这四种淋巴细胞反应的测定,在反映癌症病人的免疫状态和指示病情、考核疗效上,并非理想指标。
The use of LCN, ERFC, LCT, LCM and other indicators observed in newly diagnosed cancer patients without anti-cancer treatment of immune status than the normal tendency to reduce the metastasis of patients with metastasis compared with non-metastasis, lymphocyte reaction was somewhat lower, However, most of the indexes had no statistical significance. Compared with newly diagnosed patients, radiotherapy had inhibitory effects on ERFC, LCT and LCM in patients with different anticancer treatment, LCN and ERFC decreased in chemotherapy patients, only LCT decreased in Chinese herbal medicine anticancer drugs, and surgical treatment And the combination therapy showed no significant change in the immune indicators of lymphocytes and the patient’s condition after treatment development is not entirely consistent, therefore, the determination of these four lymphocyte reactions, reflecting the immune status of cancer patients and instructions Condition, assessment of efficacy, is not an ideal indicator.